We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Glaxosmithkline Renews and Expands Global License for Simulations Plus Software
News

Glaxosmithkline Renews and Expands Global License for Simulations Plus Software

Glaxosmithkline Renews and Expands Global License for Simulations Plus Software
News

Glaxosmithkline Renews and Expands Global License for Simulations Plus Software

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Glaxosmithkline Renews and Expands Global License for Simulations Plus Software"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Simulations Plus, Inc. has announced that GlaxoSmithKline (GSK) has renewed its global multi-year license for Simulations Plus software and has added a new site at its Parsippany, NJ location.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “GSK was one of the first GastroPlus™ customers back in 1998 and probably has the largest number of scientists who have gone through GastroPlus training over the years – somewhere in the hundreds.  GSK’s scientists are among the most expert users of GastroPlus in the industry, and they have published scientific papers and posters referencing their use of GastroPlus in their important research.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “We appreciate the continued confidence GSK has shown in Simulations Plus over the years, as well as suggestions for improvement they have provided that are now standard features in our programs.  This is a time of growing use of simulation and modeling tools in pharmaceutical research, and GSK has been one of the companies at the forefront.  We look forward to continuing the excellent relationships we have with GSK scientists worldwide.”

Advertisement